Mid-Regional Pro-Adrenomedullin and N-Terminal Pro-B-Type Natriuretic Peptide Measurement: A Multimarker Approach to Diagnosis and Prognosis in Acute Heart Failure.
C-reactive protein (CRP)
N-terminal pro-B-type natriuretic peptide (NT-proBNP)
acute heart failure (AHF)
creatinine
mid-regional pro-adrenomedullin (MR-proADM)
Journal
Journal of personalized medicine
ISSN: 2075-4426
Titre abrégé: J Pers Med
Pays: Switzerland
ID NLM: 101602269
Informations de publication
Date de publication:
18 Jul 2023
18 Jul 2023
Historique:
received:
16
05
2023
revised:
06
07
2023
accepted:
12
07
2023
medline:
29
7
2023
pubmed:
29
7
2023
entrez:
29
7
2023
Statut:
epublish
Résumé
Acute heart failure (AHF) is a major cause of hospitalization and mortality worldwide. Early and accurate diagnosis, as well as effective risk stratification, are essential for optimizing clinical management and improving patient outcomes. In this context, biomarkers have gained increasing interest in recent years as they can provide important diagnostic and prognostic information in patients with AHF. The primary objective of the present study was to compare the levels of N-terminal pro-B-type natriuretic peptide (NT-proBNP), mid-regional pro-adrenomedullin (MR-proADM), and C-reactive protein (CRP) between patients diagnosed with acute heart failure (AHF) and those without AHF and sepsis. Furthermore, the study aimed to assess the diagnostic and prognostic value of the use of a multimarker approach in AHF patients. To achieve these objectives, a total of 145 patients with AHF and 127 patients without AHF and sepsis, serving as the control group, were consecutively enrolled in the study. Levels of MR-proADM (median: 2.07; (25th-75th percentiles: 1.40-3.02) vs. 1.11 (0.83-1.71) nmol/L, The combined assay of MR-proADM and NT-proBNP could be helpful in accurately identifying AHF and in defining prognosis and re-admission for AHF. The complementary use of these biomarkers can provide a useful clinical evaluation of AHF while also orienting clinicians to the pathophysiology underlying heart damage and assisting them in tailoring therapy.
Sections du résumé
BACKGROUND
BACKGROUND
Acute heart failure (AHF) is a major cause of hospitalization and mortality worldwide. Early and accurate diagnosis, as well as effective risk stratification, are essential for optimizing clinical management and improving patient outcomes. In this context, biomarkers have gained increasing interest in recent years as they can provide important diagnostic and prognostic information in patients with AHF.
AIM AND METHODS
OBJECTIVE
The primary objective of the present study was to compare the levels of N-terminal pro-B-type natriuretic peptide (NT-proBNP), mid-regional pro-adrenomedullin (MR-proADM), and C-reactive protein (CRP) between patients diagnosed with acute heart failure (AHF) and those without AHF and sepsis. Furthermore, the study aimed to assess the diagnostic and prognostic value of the use of a multimarker approach in AHF patients. To achieve these objectives, a total of 145 patients with AHF and 127 patients without AHF and sepsis, serving as the control group, were consecutively enrolled in the study.
RESULTS
RESULTS
Levels of MR-proADM (median: 2.07; (25th-75th percentiles: 1.40-3.02) vs. 1.11 (0.83-1.71) nmol/L,
CONCLUSION
CONCLUSIONS
The combined assay of MR-proADM and NT-proBNP could be helpful in accurately identifying AHF and in defining prognosis and re-admission for AHF. The complementary use of these biomarkers can provide a useful clinical evaluation of AHF while also orienting clinicians to the pathophysiology underlying heart damage and assisting them in tailoring therapy.
Identifiants
pubmed: 37511766
pii: jpm13071155
doi: 10.3390/jpm13071155
pmc: PMC10381388
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Front Med (Lausanne). 2022 Oct 26;9:929408
pubmed: 36388948
Med J Aust. 2011 Apr 18;194(8):405-9
pubmed: 21495941
J Am Coll Cardiol. 2013 Mar 12;61(10):1078-88
pubmed: 23473413
Eur Heart J. 2016 Jul 14;37(27):2129-2200
pubmed: 27206819
Mayo Clin Proc. 2023 Apr;98(4):549-558
pubmed: 37019514
Nat Rev Dis Primers. 2020 Mar 5;6(1):16
pubmed: 32139695
J Am Coll Cardiol. 2016 Dec 6;68(22):2425-2436
pubmed: 27908347
Circulation. 2011 Dec 20;124(25):2865-73
pubmed: 22104551
Circulation. 2022 May 3;145(18):e895-e1032
pubmed: 35363499
Circulation. 2019 May 7;139(19):2285-2288
pubmed: 30955360
Health Technol Assess. 2009 Jul;13(32):1-207, iii
pubmed: 19586584
Clin Chem. 2005 Oct;51(10):1823-9
pubmed: 16099941
N Engl J Med. 2019 Feb 7;380(6):539-548
pubmed: 30415601
Indian J Nephrol. 2021 May-Jun;31(3):212-217
pubmed: 34376932
Circ Cardiovasc Qual Outcomes. 2018 Dec;11(12):e005083
pubmed: 30562071
PLoS One. 2021 Feb 8;16(2):e0246771
pubmed: 33556140
Circ Res. 2013 Aug 30;113(6):646-59
pubmed: 23989710
Nat Commun. 2020 Jul 17;11(1):3595
pubmed: 32681081
N Engl J Med. 2008 May 15;358(20):2148-59
pubmed: 18480207
Am J Physiol. 1998 Sep;275(3):F410-4
pubmed: 9729514
Microb Pathog. 2019 Dec;137:103763
pubmed: 31574301
BMJ Open. 2019 Jan 7;9(1):e022972
pubmed: 30617099
Lancet. 2018 Nov 10;392(10159):1789-1858
pubmed: 30496104
Eur J Heart Fail. 2011 May;13(5):518-27
pubmed: 21422000
J Pers Med. 2023 Jan 11;13(1):
pubmed: 36675802
Eur J Heart Fail. 2002 Aug;4(4):531-9
pubmed: 12167394
Circulation. 2020 Mar 3;141(9):e139-e596
pubmed: 31992061
Cardiol Res Pract. 2016;2016:3708210
pubmed: 27022499
Crit Care. 2006;10(3):R73
pubmed: 16696865
Int J Cardiol. 2013 Oct 3;168(3):2186-94
pubmed: 23538053
BMC Cardiovasc Disord. 2017 Aug 3;17(1):215
pubmed: 28774268
Circulation. 2007 Jun 19;115(24):3103-10
pubmed: 17548729
Circulation. 2018 Mar 20;137(12):e67-e492
pubmed: 29386200
Saudi J Kidney Dis Transpl. 2019 Mar-Apr;30(2):376-386
pubmed: 31031374
Eur Heart J. 2021 Sep 21;42(36):3599-3726
pubmed: 34447992
Heart. 2007 Sep;93(9):1137-46
pubmed: 17699180
Congest Heart Fail. 2011 Jul-Aug;17(4):169-74
pubmed: 21790966
N Engl J Med. 2009 Mar 19;360(12):1179-90
pubmed: 19297571
Eur J Heart Fail. 2016 Mar;18(3):242-52
pubmed: 26727047
Circulation. 2009 Apr 14;119(14):e391-479
pubmed: 19324966
J Am Coll Cardiol. 2001 Dec;38(7):2101-13
pubmed: 11738322
Circulation. 2004 Apr 13;109(14):1789-94
pubmed: 14967720
Eur J Heart Fail. 2013 Jul;15(7):808-17
pubmed: 23537547
Biochim Biophys Acta. 2013 Dec;1832(12):2442-50
pubmed: 23313577
Lancet. 2018 Feb 10;391(10120):572-580
pubmed: 29174292
Eur Heart J. 2012 Sep;33(17):2197-205
pubmed: 22645194
Circulation. 2009 Feb 3;119(4):515-23
pubmed: 19153268
J Am Heart Assoc. 2019 Dec 3;8(23):e014240
pubmed: 31771438
Peptides. 1997;18(5):733-9
pubmed: 9213369